The Filing Desk

Aquestive Therapeutics vs Nektar Therapeutics

Aquestive Therapeutics AQST · Nektar Therapeutics NKTR · Pharmaceuticals

Nektar Therapeutics reported revenue of $55 million in fiscal 2025, 1.2 times Aquestive Therapeutics' $44 million in fiscal 2025. Aquestive Therapeutics' revenue fell 22.6% in its latest year, and Nektar Therapeutics' fell 43.9%. Aquestive Therapeutics had an operating margin of -159.5%, against -253.7% at Nektar Therapeutics. Free cash flow was −$53 million at Aquestive Therapeutics and −$209 million at Nektar Therapeutics.

Side by side

Aquestive TherapeuticsNektar Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$44M$55M
Revenue growth−22.6%−43.9%
Revenue growth a year, last 5 years−0.6%−18.4%
Gross margin58.4%100.0%
Operating margin−159.5%−253.7%
Net margin−188.1%−297.1%
Free cash flow−$53M−$209M
Free cash flow margin−119.0%−377.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count23.3%23.1%
Last close$3.91$37.27
P/E at the last close——
Insider trades, last 12 months—sold $2.4 million
Piotroski F-score2 of 92 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Aquestive TherapeuticsNektar Therapeutics
Operating margin
Percent of revenue
Aquestive TherapeuticsNektar Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aquestive TherapeuticsNektar Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aquestive Therapeutics and Nektar Therapeutics pages.